Intelligence Report · ~12 min read
Tyra Biosciences Intelligence Report
Generated from 2 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
4 items
Sources
5
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Tyra Biosciences maintains an active intelligence profile across Oncology, Urothelial Carcinoma, Bladder Cancer. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with moderate portfolio impact. Evidence coverage stands at 72% across 2 tracked sources. Highest-priority development: FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. Regulatory precedent. Why this matters: sets a safety guidance precedent in the same sub-indication (bladder cancer) as Tyra Biosciences.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Ongoing | Cancer Accelerated Approvals
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 39 with buyer quality 8 (Mid-Market). Competitive pressure: Low. Portfolio impact: Moderate.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceOngoing | Cancer Accelerated Approvals
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Tyra Biosciences initiates Phase 2A/B trial of Dabogratinib for Low Grade Upper Tract Urothelial Carcinoma
Oncology · Urothelial Carcinoma
- Phase 2 Study of TYRA-300 Shows Promise for FGFR3 Altered NMIBC
Oncology · Bladder Cancer